A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer

A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer is a phase 2, randomised interventional study registered as NCT07301229 by Shanghai Henlius Biotech, with a registry enrolment figure of 100 participants, started 2025-12-29 and due to reach its primary completion in 2028-02-21. Interventions recorded: HLX43 DOSE 1 (2.5 mg/kg); HLX43 DOSE 2 (3.0 mg/kg). Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC). Primary outcome: ORR; PFS. Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed, unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC),who has failed at least one prior line of standard systemic therapy". No results are recorded here; the registry entry is the source.